MAPK14 and colorectal cancer: Previous researches have demonstrated that inhibition of autophagy augments anticancer effects of chemotherapy or some targeted therapies in colorectal cancer.37, 38 Recently, it has been shown that mitogen-activated protein kinase 14 (MAPK14)/p38α is involved in resistance of colon cancer cells to 5-FU and irinotecan, which triggers survival-promoting autophagy to protect tumor cells against the cytotoxic effects of these drugs.39, 40 Furthermore, autophagy inhibitor CQ significantly enhances the 5-FU-induced inhibition of tumor growth both in vitro and in vivo.